MicroRNAs in oral cancer: Biomarkers with clinical potential.

Oral cancer is the sixteenth most common cancer globally, with a relatively poor five-year survival rate of 50%. Thus it is imperative to understand the biology of oral cancer and examine alternative prognostic and therapeutic targets for oral cancer. MicroRNAs (miRNAs) are small non-coding RNAs mediating gene expression at the post-transcriptional level through mRNA degradation or translational repression. miRNAs play an essential role in cancer development and oncogenic cell processes. miRNA deregulation is observed in oral cancer and associated with prognosis. However, the role of miRNAs and their clinical implications in oral cancer is not clear. The current review highlights the miRNA profile of oral cancer and discusses the diagnostic, prognostic and potential therapeutic targets with clinical implications. miRNAs mediate activation or suppression of signalling pathways associated with oral cancer. Hence, a panel of select deregulated miRNAs may indicate clinicopathological features, personalised treatment outcome and provide novel lead profiles of oral cancer. The translational applications of miRNAs may lead to better management and survival of oral cancer patients. The compiled data provides a platform for consideration of miRNA signatures as potential biomarkers for early oral cancer diagnosis, prognosis and as novel molecular therapies.

High-Risk Human Papillomavirus in Oral Cancer: Clinical Implications.

Oral cancer is the eleventh most common cancer globally, with well-established major risk factors of tobacco, areca nut, alcohol, and high-risk human papillomavirus (HR-HPV) types 16 and 18. HR-HPV16/18 are the etiologic agents of cervical cancers and a proportion of oropharyngeal cancers. HPV-associated oropharyngeal and oral cancers show better prognosis and response to therapy. However, the picture of HR-HPV16/18 and the clinical implications of oral cancers are not clear with the majority of reports combining oral cancer data with head and neck cancers. The current review compiles the global prevalence of HR-HPV16/18 in oral cancers, highlighting the unique clinical and molecular pathologic features, prognosis and therapeutic strategies in the prevention and management of HPV-positive oral cancers. The potential for the use of de-intensified therapy and prophylactic prevention in HPV-positive oral cancer patients is highlighted.

Single nucleotide polymorphisms in an Indian cohort and association of CNTN4, MMP2 and SNTB1 variants with oral cancer.

Oral cancer is a high incidence cancer in India primarily due to the prevalent tobacco/areca nut chewing habits and hence a major health concern. India constitutes 26% of the global oral cancer burden. Besides the well-established risk factors, the genomic constitution of an individual plays a role in oral cancer. The aim of the current study was to analyse genomic variants represented as single nucleotide polymorphisms (SNPs), analyse their prevalence and investigate risk association of allelotypes/genotypes to oral cancers. Eleven SNPs in genes associated with biological functions were analysed in an Indian cohort (n = 1000) comprising 500 oral cancer patients and 500 long term tobacco habitués as controls, using Allelic discrimination Real-Time PCR assay with SYBR Green dye. Fisher's exact test and Odds Ratio were used for statistical analysis. Increased risk was observed for rs9849237 CC [P = 0.008; OR 1.412 (1.09-1.82)] and rs243865 CT [P = 0.004; OR 1.469 (1.13-1.90)] genotypes, whereas rs9849237 CT [P = 0.034; OR 0.755 (0.58-0.97)], rs243865 CC [P = 0.002; OR 0.669 (0.51-0.86)] and rs10090787 CC [P = 0.049; OR 0.774 (0.60-0.99)] genotypes indicated decreased risk to oral cancer. The other SNPs showed equidistribution in both groups. Our data indicated genotypes and alleles in specific SNPs rs9849237, rs243865 and rs10090787 with increased/decreased risk to oral cancer.